US2006062759A1PendingUtilityA1

Method of cancer screening; method of cancer treatment; and method of diabetes treatment

Individually held — no corporate assignee on recordPriority: Sep 21, 2004Filed: Oct 27, 2005Published: Mar 23, 2006
Est. expirySep 21, 2024(expired)· nominal 20-yr term from priority
Inventors:John Woodward
A61K 38/191A61K 31/522A61K 39/0008A61K 31/4745
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood tumor cell count. If all of the foregoing steps are positive, the cancer is treated by applying imiquimod transdermally to rotating sites, preferably by mixing ALDARA™ (imiquimod) 5% cream with an equal amount of H base cream™; administering a vaccine containing tumor necrosis factor alpha, preferably the BCG vaccine; and orally administering VALTREX™ (valacyclovir) twice daily. The foregoing treatment method is also effective in treating Type I diabetes, MS, and other epidermal cancers.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled)  
   
   
       11 . A method of treating multiple sclerosis comprising the steps of: 
 providing a quantity of ALDARA™ (imiquimod) 5% cream;    providing a quantity of H base cream™;    mixing ¼ cc. of the ALDARA™ (imiquimod) 5% cream with ¼ cc. of the H base cream™ and transdermally administering the resulting mixture to the patient;    administering a vaccine containing tumor necrosis factor; and    orally administering VALTREX™ (valacyclovir) tablets.    
   
   
       12 . The method of treating multiple sclerosis according to claim  9  wherein the ALDARA™ (imiquimod) 5% cream/H base cream mixture is applied daily, the vaccine containing tumor necrosis factor is administered every three weeks and 500 mg VALTREX™ (valacyclovir) tablets are orally administered twice daily.

Join the waitlist — get patent alerts

Track US2006062759A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.